Sandra A. Edwards (State Bar No. 154578)
Joshua W. Malone (State Bar No. 301836)
Farella Braun + Martel LLP
235 Montgomery Street, 17th Floor
San Francisco, CA 94104
Telephone: (415) 954-4400; Fax: (415) 954-4480
sedwards@fbm.com
jmalone@fbm.com

Joe G. Hollingsworth (appearance pro hac vice)
Martin C. Calhoun (appearance pro hac vice)
Kirby T. Griffis (appearance pro hac vice)
William J. Cople (appearance pro hac vice)
Hollingsworth LLP
1350 I Street, N.W.
Washington, DC 20005
Telephone: (202) 898-5800; Fax: (202) 682-1639
jhollingsworth@hollingsworthllp.com
mcalhoun@hollingsworthllp.com
kgriffis@hollingsworthllp.com
wcople@hollingsworthllp.com

George C. Lombardi (appearance pro hac vice)
James M. Hilmert (appearance pro hac vice)
Winston & Strawn LLP
35 West Wacker Drive
Chicago, IL 60601
Telephone: (312) 558-5969; Fax: (312) 558-5700
glombard@winston.com
jhilmert@winston.com

Attorneys for Defendant
MONSANTO COMPANY

SUPERIOR COURT OF THE STATE OF CALIFORNIA
COUNTY OF SAN FRANCISCO

DEWAYNE JOHNSON,
Plaintiff,

vs.

MONSANTO COMPANY,
Defendant.

Case No. CGC-16-550128

EXHIBITS 46 THROUGH 47 TO THE DECLARATION OF SANDRA A. EDWARDS IN SUPPORT OF MONSANTO'S MOTIONS IN LIMINE NOS. 6-30

Trial Date: June 18, 2018
Time: 9:30 p.m.
Department: TBD

EXHIBITS TO DECLARATION OF SANDRA A. EDWARDS IN SUPPORT OF MONSANTO'S MOTIONS IN LIMINE NOS. 6-30 - Case No. CGC-16-550128
Letter to the editor

To the attention of Wallace Hayes.

Dear Editor of Food and Chemical Toxicology,

The Société Française de Pathologie Toxicologique (SFPT, French Society of Toxicologic Pathology, toxpathfrance.org) is a non governmental/non profit organization formed by veterinarians, physicians, pharmacists and biologists specialized in veterinary and toxicologic pathology. Its aim is to promote knowledge in pathology, toxicology and laboratory animal sciences for safety studies of drugs, chemicals and food products, and the role of the pathologist in the study design and data interpretation. As such, the SFPT feels compelled to point out weaknesses in the paper by Séràlini et al. (2012), the number and importance of which make the study reported very difficult to interpret scientifically. We are aware that more arguments can be found in other scientific disciplines.

Before concentrating on veterinary and pathology aspects, we wish to briefly comment on two points. Regarding the statement that "the authors declare that there are no conflicts of interest", we respectfully disagree: Pr Gilles-Eric Séràlini being President of the Scientific Board of the CRIGEN, and the CRIGEN having been a "major support" of the study, it seems to us that this should have been disclosed. Regarding the English, several native-English speaking colleagues complained about the difficulty to read the text because of many gross errors in expression: we consider that the journal reviewers could have alerted the authors on this point.

In our opinion, the study as reported (Ethics, §2.1) demonstrate a critical failure in the ethical supervision. First, it is not clear that the protocol was reviewed by a Committee of Animal Ethics/Institutional Animal Care and Use Committee, a basic requirement in the industry to even allow the purchasing of laboratory animals. "Animal experiments were performed according to ethical guidelines..." is not the same than stating that the protocol and the procedures were approved by an Ethical Committee. This is especially important in view of the statement that 31 parameters were analyzed (Biochemical analyses, §2.4): the quantity of blood removed is not indicated, and this could have had an effect on the well being of the animals and on their sanitary status. Clear guidelines of limits on blood sampling are available in the literature (Diehl et al., 2001), but it is impossible to know if they were followed in the study. Then, the choice of a low number of animals per group, thereby not following published guidelines (OECD, 2008, 2009), can be criticized as the data generated cannot be analyzed according to the state of the art methods and animals will have been used for no purpose, thus not respecting the humane principle of reduction (Russell and Burch, 1959). Last but not least, we were shocked at reading the ethical rules followed for euthanasia ("25% body weight loss, tumors over 25% body weight..." leading to euthanasia; Anatopomorphologie, §2.5) and at looking at Fig. 3J-L: the size of the tumors, with skin erosions and ulcerations, having certainly an impact on movement, feeding and pain, is unacceptable under well-known guidelines (Workman et al. 1998). This should have led to a much earlier euthanasia with respect to ethical humane concerns and casts doubts about the "careful monitoring" (Anatomopathological observations, §3.2) of animals. No argument, apparently to leave tumors develop as much as possible, should have prevailed. Again this demonstrates a lack of understanding of animal physiology and ethics, and a lack of supervision by the Ethical Committee and by a site veterinarian ("vétérinaire sanitaire", a function mandatory under French law, see Article R203-1 5°). We are surprised that these major ethical issues were not clarified during the review that the paper underwent before approval for publication.

We lack a clear understanding of the procedure followed for the pathologic examination of tissues. Especially, we have no idea, given the authors’ affiliations, of who performed this pathologic examination. Also, for toxicology and carcinogenicity studies like this one, there are best practices available for primary reading (Crissman et al. 2004) and for peer review (Morton et al., 2010). The errors due to the lack of use of internationally recognized nomenclature and diagnostic criteria (as can be seen in the use of the term nephroblastoma in legend from Table 2 being called Wilm's tumor in the text, and in its erroneous assessment as GMO-related while it is an embryonal tumor found in young rodents) could have been avoided by following those best practices. The SFPT has among its members scientists from the industry, academia and also independent consultants. It would be happy to supply names of renowned colleagues, French or foreign, with a track record of assessment of toxicology and carcinogenicity studies, who would have increased the quality of the pathologic assessment and the overall value of this study.

We already hinted at deficiencies in the study design: from a statistical perspective, this long term study is largely underpowered with only 10 animals per sex per group, while the accepted guidelines (OECD, 2008, 2009) recommend using groups of at least 50 animals per sex per group, and define strict survival rate criteria that the groups must respect for the results to be considered valid. With mortality rates of 50 or 70% in some groups, we wonder whether these criteria were consistently met. As far as we understand, all results are based on descriptive analyses such as per cent age calculation, but there was no thorough mortality analysis (how to compare 3/10 with 5/10?) nor tumor incidence and date of onset analysis with recognized statistical methods (Peto et al., 1980). Not taking into account the high variability (because of the small size
of the groups) makes all reported incidences and further conclusions non-meaningful and leads the authors to a gross over interpretation of the pathology data.

We are puzzled by the inclusion of organ weights: in carcinogenesis studies, geriatric changes and, at later stages, the development of tumors confound the usefulness of organ weight data, which are therefore not recommended (OECD, 2008). We are also puzzled by the mention of 2 tumors beginning to “reach a large size ... up to 600 days earlier in 2male groups eating the GM maize”: we understand that those 2 males are the ones affected early with the nephroblastos mentioned above, and this confirms us in our analysis of the origin and absence of treatment relationship of those tumors.

As the paper reports a de facto carcinogenesis study, we expected to see some of the classical objectives of such a study type: the identification of the carcinogenic properties of a chemical; the identification of target organs; the characterization of a dose–response relationship; the identification of a no-observed (adverse) effect level (NOAEL); the prediction of carcinogenic effects of a chemical at human exposure levels; understanding the mode of action for treatment-related findings. We do not find in the results and in the discussion all the information necessary to meet these objectives; especially the non-conventional data reporting, with only an extract of the study data, and the data presentation, with merging of various pathological entities in Table 2 and focus on non-relevant findings, prevent us to make a scientific evaluation of the objectives discussed above. A full incidence list of all tumors by type, sex and group would have been more useful than a full plate of photos.

We spotted other errors in the Anatomopathological observations (§3.2): presenting incomplete neoplastic and non-neoplastic findings; considering hepatic foci of altered cells as necrotic foci; hepatic congestion being not relevant if the rats were found dead or moribund; diagnosing macroscopic necrotic foci; presenting common neoplasms in treated animals as treatment-specific; not presenting historical data (particularly useful in this case given the small group size); noting a difference between photos 1 and 2 in Fig. 4, and reporting the increase in smooth endoplasmic reticulum while this change should be regarded as adaptive to xenobiotic metabolism (in the absence of contrary evidence); not presenting a mechanism for the increase in glycogen noted on the EM photos (especially in the absence of fasting status of the animals at euthanasia); lacking to critically discuss the pituitary tumors and the mammary tumors (prolactin-dependent); lacking to critically discuss the chronic progressive nephropathy in old rats. This list is not exhaustive, but is enough to cast doubts about the value of all the anatomopathological results.

In conclusion, the SFFT is deeply convinced that a thorough evaluation of all products is necessary before marketing but also during the product life, in order to guarantee as much as possible human, animal and environment safety. However, given this study presents serious deficiencies in the protocol, the procedures and the interpretation of the results, the SFFT cannot support any of the scientific claims drawn by the authors, and any relevance for human risk assessment.

This letter presents the consensus scientific opinion of the Conseil d’Administration of the SFFT.

References


Further reading

For all pathology data not substantiated by a reference, please refer to recent and comprehensive toxicologic pathology textbooks, such as Greaves, 2012. Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation, fourth ed. Academic Press, New York.

Erio Barale-Thomas
Président du Conseil d’Administration du SFFT
E-mail address: president@toxpathfrance.org

Available online 16 November 2012
EXHIBIT 47
Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize

Gilles-Eric Seralini a,*, Emilie Clair a, Robin Mesnage a, Steeve Gress a, Nicolas Defarge a, Manuela Malatesta b, Didier Hennequin c, Joël Sprioux de Vendémois a

a University of Caen, Institute of Biology, CRIGEN and Risk Pole, MRSH-CNRS, EA 2608, Esplanade de la Paix, Caen Cedex 14032, France
b University of Verona, Department of Neurological, Neuropsychological, Morphological and Motor Sciences, Verona 37134, Italy
c University of Caen, UK ABTE, EA 4651, Bd Maréchal Juin, Caen Cedex 14032, France

ARTICLE INFO

Article history:
Received 11 April 2012
Accepted 2 August 2012
Available online xxx

Keywords:
GMO
Roundup
NK603
Rat
Glyphosate-based herbicides
Endocrine disrupting effects

ABSTRACT

The health effects of a Roundup-tolerant genetically modified maize (from 11% in the diet), cultivated with or without Roundup, and Roundup alone (from 0.1 ppb in water), were studied 2 years in rats. In females, all treated groups died 2–3 times more than controls, and more rapidly. This difference was visible in 3 male groups fed GMOs. All results were hormone and sex dependent, and the pathological profiles were comparable. Females developed large mammary tumors almost always more often than and before controls, the pituitary was the second most disabled organ; the sex hormonal balance was modified by GMO and Roundup treatment. In treated males, liver congestions and necrosis were 2.5–5.5 times higher. This pathology was confirmed by optic and transmission electron microscopy. Marked and severe kidney nephropathies were also generally 1.3–2.3 greater. Males presented 4 times more palpable tumors than controls which occurred up to 600 days earlier. Biochemistry data confirmed very significant kidney chronic deficiencies; for all treatments and both sexes, 76% of the altered parameters were kidney related. These results can be explained by the non linear endocrine-disrupting effects of Roundup, but also by the overexpression of the transgene in the GMO and its metabolic consequences.

© 2012 Elsevier Ltd. All rights reserved.

1. Introduction

There is an ongoing international debate as to the necessary length of mammalian toxicity studies in relation to the consumption of genetically modified (GM) plants including regular metabolic analyses (Seralini et al., 2011). Currently, no regulatory authority requests mandatory chronic animal feeding studies to be performed for edible GMOs and formulated pesticides. However, several studies consisting of 90 day rat feeding trials have been conducted by the biotech industry. These investigations mostly concern GM soy and maize that are rendered either herbicide tolerant or Roundup (R) in 80% of cases, or engineered to produce a modified Bt toxin insecticide, or both. As a result these GM crops contain new pesticide residues for which new maximal residual levels (MRL) have been established in some countries.

If the petitioners conclude in general that there is no major change in genetically modified organism (GMO) subchronic toxicity studies (Domingo and Giné Bordona, 2011; Hammond et al., 2004, 2006a,b), significant disturbances have been found and may be interpreted differently (Seralini et al., 2009; Sprioux de Vendémois et al., 2010). Detailed analyses have revealed alterations in kidney and liver functions that may be the signs of early chronic diet intoxication, possibly explained at least in part by pesticide residues in the GM feed (Seralini et al., 2007; Sprioux de Vendémois et al., 2009). Indeed, it has been demonstrated that R concentrations in the range of $10^3$ times below the MRL induced endocrine disturbances in human cells (Gasnier et al., 2009) and toxic effects thereafter (Benachour and Seralini, 2009), including in vivo (Romano et al., 2012). After several months of consumption of an R-tolerant soy, the liver and pancreas of mice were affected, as highlighted by disturbances in sub-nuclear structure (Malatesta et al., 2008a, 2002a,b). Furthermore, this toxic effect was reproduced by the application of R herbicide directly to hepatocytes in culture (Malatesta et al., 2008b).
In addition, cytochrome activities also generally increased in the presence of R (in drinking water or GM diet) according to the dose up to 5.7 times at the highest dose. Transmission electron microscopic observations of liver samples confirmed changes for all treated groups in relation to glycogen dispersion or appearance in livers, increase of residual bodies and enlargement of cristae in mitochondria (Fig. 4). The GM maize fed groups either with or without R application (in plants) showed a reduced transcription in mRNA and rRNA because of higher heterochromatin content, and decreased nucleolar dense fibrillar components. In the GMO+R group (at the highest dose) the smooth endoplasmic reticulum was drastically increased and nucleoli decreased in size,